Youningwei: Announcement on the completion of some fundraising projects and the remaining raised funds to permanently replenish working capital
Securities code: 301166 Securities abbreviation: Youningwei Announcement number: 2025-096
Shanghai Youningwei Biotechnology Co., Ltd.
Announcement on the completion of some fundraising projects and the remaining raised funds to permanently replenish working capital
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Shanghai Uniview Biotechnology Co., Ltd. (hereinafter referred to as the "Company") on December 30, 2025 The 10th meeting of the fourth session of the Board of Directors was held on the same day, and the "Proposal on Closing Part of the Raised Investment Projects and Permanently Replenishing Working Capital with the Surplus Raised Funds" was reviewed and approved. The company's initial public offering of stocks raised funds to invest in the R&D center construction project "Aibixin (Shanghai) Biotechnology Co., Ltd. Laboratory Construction Project" and "Shanghai Le The "Laboratory Adjustment Project of Beishi Biotechnology Co., Ltd." has reached the scheduled usable state. The company's board of directors agrees to close the above-mentioned investment projects and use the remaining raised funds to permanently supplement working capital for the company's daily operating activities. At the same time, the relevant special account for raised funds will be canceled and the relevant raised funds supervision agreement will be terminated. The specific situation is now announced as follows:
1. Basic information on raised funds and investment projects
(1) Basic information on raised funds
With the approval of the "Reply on the Registration of the Initial Public Offering of Stocks of Shanghai Youningwei Biotechnology Co., Ltd." (CSRC Permit [2021] No. 3556) issued by the China Securities Regulatory Commission, and with the consent of the Shenzhen Stock Exchange, the company's initial public offering of 21,666,668 RMB ordinary shares (A shares), with a face value of RMB 1.00 per share, an issue price of RMB 86.06 per share, and a total amount of funds raised of RMB 86.06 per share. 1,864,633,400 yuan. After deducting the issuance expenses of RMB 269,116,200 (excluding tax), the actual net amount of funds raised was RMB 1,595,517,300.
All the above-mentioned raised funds have been received. Baker Tilly International Accounting Firm (Special General Partnership) has verified the arrival of the above-mentioned funds and issued the Capital Verification Report No. [2021] 45819.
(2) Basic information on fundraising projects
According to the "Prospectus for Initial Public Offering of Stocks and Listing on GEM" disclosed by the company, the company's investment projects and use plan of funds raised from the initial public offering of stocks are as follows:
Unit: 10,000 yuan
Planned fundraising serial number, project name, total investment
Amount of funds 1 Online marketing network and information construction project 8,079.60 8,079.60 2 Offline marketing and service network upgrade project 6,828.15 6,828.15 3 R&D center construction project 8,431.58 8,431.58 3.1 Protein and antibody reagent R&D technical improvement project 5,429.08 5,429.08 3.2 Laboratory construction project of Aibixin (Shanghai) Biotechnology Co., Ltd. 1,552.40 1,552.40 3.3 Laboratory adjustment project of Shanghai Lebishi Biotechnology Co., Ltd. 1,450.10 1,450.10 4 Supplementary working capital project 5,000.00 5,000.00
Total 28,339.33 28,339.33
Note: If there is any difference in the mantissa between the total and the direct sum of each component in the above table, it is due to rounding.
2. Storage and management of raised funds
(1) Management of raised funds
In order to standardize the management and use of funds raised by companies and protect the rights and interests of investors, in accordance with the "Capital Raising by Listed Companies"
"Financial Supervision Rules", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies"
In accordance with the provisions of the Company's Self-Regulatory Guidelines No. 2 - Standardized Operations of GEM Listed Companies and other relevant laws, regulations and normative documents as well as the company's "Measures for the Management of Raised Funds", the company has opened a special account for raised funds.
The raised funds are stored in a special account and signed with the sponsor institution Minsheng Securities Co., Ltd. and commercial banks.
"Tripartite Supervision Agreement on Raised Funds".
(2) Storage status of raised funds in special accounts
As of November 30, 2025, the opening and existence of the company's special account for raised funds are as follows:
Balance of raised funds
Account status Purpose of raised funds Special account number Opening bank
(yuan)
Online marketing network and information construction
Shanghai Pudong Development Bank shareholding project; offline marketing and service network upgrade 98250078801000002003 45,006,590.97 Nanshi Branch of Surviving Co., Ltd.
level project
Ping An Bank Co., Ltd.'s supplementary working capital project 15960351896868 0.00 Canceled Shanghai Pilot Free Trade Zone Branch
R&D center construction project: Aibixin
Ping An Bank Co., Ltd. This planned injection of (Shanghai) Biotechnology Co., Ltd. 15967251896833 0.00
Shanghai Pilot Free Trade Zone Branch and Sales Laboratory Construction Project
Ping An Bank Co., Ltd. 15868951896886 9,009.20 Surviving R&D center construction project: protein and antibiotics Shanghai Free Trade Pilot Zone Branch
Technical transformation project for body reagent research and development Shanghai Pudong Development Bank Co., Ltd. 98250078801100003339 25,216,225.21 Nanshi Branch of Surviving Co., Ltd.
R&D center construction project: Shanghai Lebei
Ping An Bank Co., Ltd. This time it is planned to inject the laboratory of Biotechnology Co., Ltd. 15985751896892 2,350,114.46
Shanghai Pilot Free Trade Zone Marketing Adjustment Project
Self-owned brand product production base project Industrial and Commercial Bank of China Co., Ltd. 4301020519100310919 1,182,657.16 Survival (biological preparations production line construction project) Nanjing Zhongjie Branch of the Company
Over-raised funds of China Merchants Bank Co., Ltd. 121923691110118 0.00 Closed account at Shanghai Siping Branch
China Minsheng Banking Co., Ltd. Super-raised funds 687006988 0.00 Shanghai Branch of the company that has been closed
Bank of China Co., Ltd. over-raised funds 439082459340 0.00 Closed account at Shanghai Xintiandi Branch
Note: R&D center construction project: The special account for protein and antibody reagent R&D technical transformation projects (15868951896886) has been canceled on December 4, 2025.
3. Usage and savings of funds raised for this closed investment project
In view that the company's R&D center construction project "Laboratory Construction Project of Aibixin (Shanghai) Biotechnology Co., Ltd." and "Laboratory Adjustment Project of Shanghai Lebeishi Biotechnology Co., Ltd." have reached the scheduled usable status, the company plans to close the above-mentioned investment projects. As of November 30, 2025, the use of funds raised from the above projects is as follows:
Unit: RMB 10,000 raised capital commitment Cumulative raised funds used Bank interest after deducting handling fees Name of the remaining funds in the account
Total investment (A) Total funds raised (B) and net cash management income (C) Amount (D=A-B+C) Laboratory construction of Aibixin (Shanghai) Biotechnology Co., Ltd.
1,552.40 1,596.04 43.64 0 items
Laboratory adjustment project of Shanghai Lebishi Biotechnology Co., Ltd.
1,450.10 1,288.80 73.71 235.01 Note (1): The actual amount of surplus raised funds shall be based on the balance of the special account on the day when the funds are transferred out.
Note (2): If the total number of the data in this announcement does not match the sum of the sub-items, it is due to rounding.
4. The main reasons for the savings in funds raised from this closed investment project
During the construction process of "Shanghai Lebishi Biotechnology Co., Ltd. Laboratory Adjustment Project", in line with the principles of reasonableness, economy and effectiveness, and on the premise of ensuring the quality of project construction, the raised funds were used prudently, and the control, supervision and management of costs in all aspects of project construction were strengthened. Through the reasonable dispatch and optimal allocation of various resources, the overall construction cost and expense of the raised investment project were reduced.
In addition, under the premise of ensuring that the normal progress of the plan to use the raised funds and the safety of the raised funds are not affected, the company has generated a certain amount of income through reasonable arrangements for idle raised funds for cash management. At the same time, a certain amount of interest income has been generated during the storage period of the raised funds.
5. Plan for using surplus raised funds
In view that the R&D center construction projects "Laboratory Construction Project of Aibixin (Shanghai) Biotechnology Co., Ltd." and "Laboratory Adjustment Project of Shanghai Lebeishi Biotechnology Co., Ltd." have reached the scheduled usable status, in order to improve the efficiency of the use of surplus raised funds and create greater value for the company and shareholders, the company plans to use the surplus raised funds from the above-mentioned investment projects totaling 2.3501 million yuan (the actual amount shall be based on the balance on the day when the funds are transferred) to permanently supplement working capital for daily production and operation activities.
According to the regulatory requirements for the management and use of raised funds, after the permanent replenishment of the surplus raised funds for the above-mentioned investment projects is reviewed and approved by the board of directors, all the remaining raised funds will be used to supplement working capital. After the transfer of the surplus raised funds is completed, the company will cancel the relevant special account for raised funds. At the same time, the company authorizes the Finance Department to handle the cancellation of the special account for raised funds. After the special account is cancelled, the relevant regulatory agreements signed between the company, the sponsor institution and the account-opening bank will be terminated.
6. The impact of the remaining raised funds to permanently replenish working capital on the company
The company will close the completed investment projects and use the remaining raised funds to permanently replenish working capital for the company's daily production and operation activities. This decision is based on the company's actual production and operation conditions, is in line with the company's business development plan, and is conducive to improving the efficiency of the use of funds. It does not violate the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange on the use of funds raised by listed companies. There is no disguised change in the direction of the raised funds and damage to the interests of shareholders, and it will not have an adverse impact on the company's normal operations.
7. Implementation review procedures and related opinions
(1) Review status of the board of directors
On December 30, 2025, the company held the 10th meeting of the fourth board of directors and reviewed and approved the "Proposal on Closing Part of the Raised Investment Projects and Using the Surplus Raised Funds to Permanently Replenish Working Capital", and agreed to close the company's R&D center construction project "Aibixin (Shanghai) Biotechnology Co., Ltd. Laboratory Construction Project" and "Shanghai Lebishi Biotechnology Co., Ltd. Laboratory Adjustment Project", and use the remaining raised funds to permanently replenish working capital.
(2) Review status of special meetings of the Audit Committee and Independent Directors
After deliberation, we believe that the company will close some of the raised investment projects and use the remaining funds to permanently replenish working capital, which will help improve the efficiency of the use of raised funds, and there will be no disguised change in the investment direction of raised funds and harm to the interests of shareholders. This matter is in compliance with relevant laws, regulations and normative documents such as the "Supervisory Rules for Fund Raising by Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" and the "Articles of Association".
(3) Verification opinions of the sponsor
After verification, the sponsor believes that: the company's completion of some investment projects and the permanent replenishment of working capital with the remaining raised funds have been reviewed and approved by the company's board of directors, audit committee and independent directors at special meetings, and the necessary approval procedures have been fulfilled, and are in compliance with the requirements of laws, regulations and normative documents such as the Shenzhen Stock Exchange's GEM Stock Listing Rules, the Shenzhen Stock Exchange's Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies, and the "Supervisory Rules for Listed Companies' Raised Funds".
In summary, the sponsor has no objection to the completion of some of the company's investment projects and the remaining raised funds will be used to permanently replenish working capital.
8. Documents for reference
Resolution of the 10th meeting of the company’s fourth board of directors;
Resolution of the seventh meeting of the Audit Committee of the Company’s Board of Directors in 2025;
Resolution of the company’s fourth special meeting of independent directors in 2025;
The verification opinions of Guolian Minsheng Securities Underwriting and Sponsoring Co., Ltd. on the completion of some of the investment projects of Shanghai Youningwei Biotechnology Co., Ltd. and the remaining raised funds will permanently replenish working capital.
Announcement is hereby made.
Board of Directors of Shanghai Uniview Biotechnology Co., Ltd.
December 31, 2025